Update: 16.09.2025
Last week: 36 week 2025 (01.09.2025 - 07.09.2025)
Last full month: August 2025
| Time period | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | |||||||||
| WoW | 9 142 | 5.1% | 14.4% | 0 | 21 100 285 | 4.3% | 10.8% | 0 | 5.0% |
| MoM | 36 668 | 3.5% | 14.1% | 0.1 | 84 968 932 | 3.2% | 10.6% | -0.1 | 2.8% |
| YTD | 319 050 | 20.7% | 13.2% | 1.5 | 713 411 209 | 27.8% | 9.9% | 0.5 | 7.1% |
| MAT | 476 068 | 22.7% | 13.3% | 2.3 | 994 363 999 | 22.6% | 9.7% | 0.6 | 1.8% |
| BRAINMAX | |||||||||
| WoW | 1 878 | 8.7% | 100.0% | 0 | 6 645 929 | 10.7% | 100.0% | 0 | 8.7% |
| MoM | 8 534 | 2.0% | 100.0% | 0 | 30 008 435 | 3.6% | 100.0% | 0 | 2.0% |
| YTD | 82 380 | 87.2% | 100.0% | 0 | 285 411 359 | 83.6% | 100.0% | 0 | 87.2% |
| MAT | 121 030 | 92.6% | 100.0% | 0 | 416 643 343 | 87.8% | 100.0% | 0 | 92.6% |
| GOLDLINE PLUS | |||||||||
| WoW | 12 151 | -1.6% | 46.5% | 0.2 | 40 410 176 | -3.4% | 38.4% | 0.2 | -2.1% |
| MoM | 56 909 | -3.8% | 45.9% | -0.9 | 188 693 462 | -2.8% | 37.6% | -0.8 | -2.0% |
| YTD | 553 160 | -7.6% | 45.8% | 0.8 | 1 792 493 265 | -4.9% | 37.5% | 0.6 | -9.3% |
| MAT | 783 424 | -6.4% | 46.0% | 0.7 | 2 510 879 706 | -5.1% | 37.6% | 0 | -7.8% |
| MIGRENIUM | |||||||||
| WoW | 8 860 | 9.3% | 0.4% | 0 | 3 243 878 | 13.0% | 0.5% | 0.1 | -3.2% |
| MoM | 35 983 | 7.1% | 0.3% | 0 | 12 764 211 | 6.9% | 0.5% | 0 | 4.2% |
| YTD | 292 225 | -30.5% | 0.3% | -0.2 | 103 080 773 | -21.4% | 0.5% | -0.2 | 4.9% |
| MAT | 439 581 | -26.5% | 0.4% | -0.1 | 153 519 605 | -9.3% | 0.5% | -0.1 | 2.5% |
| MODELAX-N | |||||||||
| WoW | 25 090 | 2.6% | 20.4% | 1.3 | 14 810 752 | 6.7% | 15.3% | 1.3 | -3.9% |
| MoM | 109 386 | -0.2% | 18.8% | -0.1 | 62 929 768 | 2.9% | 14.0% | 0.3 | 0.3% |
| YTD | 1 001 608 | -3.1% | 20.0% | -2.5 | 540 692 284 | 20.5% | 14.5% | 0 | 9.1% |
| MAT | 1 431 469 | 1.1% | 20.0% | -1.3 | 751 099 291 | 28.8% | 14.2% | 0.9 | 7.5% |
| REDUXIN | |||||||||
| WoW | 8 124 | -5.1% | 31.1% | -1 | 44 387 883 | -7.6% | 42.1% | -1.6 | -2.1% |
| MoM | 40 074 | 0.3% | 32.3% | 0.7 | 219 573 916 | 1.5% | 43.8% | 1 | -2.0% |
| YTD | 382 505 | -12.5% | 31.7% | -1.2 | 2 086 951 246 | -10.6% | 43.6% | -2 | -9.3% |
| MAT | 540 608 | -9.8% | 31.8% | -0.7 | 2 917 219 702 | -7.0% | 43.7% | -0.9 | -7.8% |
| REDUXIN FORTE | |||||||||
| WoW | 2 879 | 5.8% | 11.0% | 0.8 | 13 873 591 | 7.1% | 13.2% | 1.4 | -2.1% |
| MoM | 12 848 | -2.5% | 10.4% | -0.1 | 60 988 448 | -1.5% | 12.2% | -0.1 | -2.0% |
| YTD | 122 124 | 2.7% | 10.1% | 1.2 | 560 930 736 | 9.2% | 11.7% | 1.7 | -9.3% |
| MAT | 170 576 | 2.5% | 10.0% | 1 | 769 139 399 | 8.2% | 11.5% | 1.4 | -7.8% |
| SALVISAR | |||||||||
| WoW | 11 510 | 14.5% | 1.7% | 0.2 | 6 210 171 | 13.4% | 1.7% | 0.2 | 0.1% |
| MoM | 42 810 | 13.5% | 1.4% | 0.2 | 23 255 651 | 14.8% | 1.4% | 0.2 | 1.1% |
| YTD | 419 626 | 17.2% | 1.6% | 0.3 | 213 040 363 | 45.3% | 1.6% | 0.4 | -3.0% |
| MAT | 633 221 | 24.6% | 1.7% | 0.4 | 307 409 866 | 56.6% | 1.6% | 0.5 | -4.7% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 319 050 | 20.7% | 13.2% | 1.5 | 713 411 209 | 27.8% | 9.9% | 0.5 | 7.1% |
| BRAINMAX | 82 380 | 87.2% | 100.0% | 0 | 285 411 359 | 83.6% | 100.0% | 0 | 87.2% |
| GOLDLINE PLUS | 553 160 | -7.6% | 45.8% | 0.8 | 1 792 493 265 | -4.9% | 37.5% | 0.6 | -9.3% |
| MIGRENIUM | 292 225 | -30.5% | 0.3% | -0.2 | 103 080 773 | -21.4% | 0.5% | -0.2 | 4.9% |
| MODELAX-N | 1 001 608 | -3.1% | 20.0% | -2.5 | 540 692 284 | 20.5% | 14.5% | 0 | 9.1% |
| REDUXIN CAPS | 382 505 | -12.5% | 31.7% | -1.2 | 2 086 951 246 | -10.6% | 43.6% | -2 | -9.3% |
| REDUXIN FORTE | 122 124 | 2.7% | 10.1% | 1.2 | 560 930 736 | 9.2% | 11.7% | 1.7 | -9.3% |
| SALVISAR | 419 626 | 17.2% | 1.6% | 0.3 | 213 040 363 | 45.3% | 1.6% | 0.4 | -3.0% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 476 068 | 22.7% | 13.3% | 2.3 | 994 363 999 | 22.6% | 9.7% | 0.6 | 1.8% |
| BRAINMAX | 121 030 | 92.6% | 100.0% | 0 | 416 643 343 | 87.8% | 100.0% | 0 | 92.6% |
| GOLDLINE PLUS | 783 424 | -6.4% | 46.0% | 0.7 | 2 510 879 706 | -5.1% | 37.6% | 0 | -7.8% |
| MIGRENIUM | 439 581 | -26.5% | 0.4% | -0.1 | 153 519 605 | -9.3% | 0.5% | -0.1 | 2.5% |
| MODELAX-N | 1 431 469 | 1.1% | 20.0% | -1.3 | 751 099 291 | 28.8% | 14.2% | 0.9 | 7.5% |
| REDUXIN CAPS | 540 608 | -9.8% | 31.8% | -0.7 | 2 917 219 702 | -7.0% | 43.7% | -0.9 | -7.8% |
| REDUXIN FORTE | 170 576 | 2.5% | 10.0% | 1 | 769 139 399 | 8.2% | 11.5% | 1.4 | -7.8% |
| SALVISAR | 633 221 | 24.6% | 1.7% | 0.4 | 307 409 866 | 56.6% | 1.6% | 0.5 | -4.7% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 9 142 | 5.1% | 14.4% | 0 | 21 100 285 | 4.3% | 10.8% | 0 | 5.0% |
| BRAINMAX | 1 878 | 8.7% | 100.0% | 0 | 6 645 929 | 10.7% | 100.0% | 0 | 8.7% |
| GOLDLINE PLUS | 12 151 | -1.6% | 46.5% | 0.2 | 40 410 176 | -3.4% | 38.4% | 0.2 | -2.1% |
| MIGRENIUM | 8 860 | 9.3% | 0.4% | 0 | 3 243 878 | 13.0% | 0.5% | 0.1 | -3.2% |
| MODELAX-N | 25 090 | 2.6% | 20.4% | 1.3 | 14 810 752 | 6.7% | 15.3% | 1.3 | -3.9% |
| REDUXIN CAPS | 8 124 | -5.1% | 31.1% | -1 | 44 387 883 | -7.6% | 42.1% | -1.6 | -2.1% |
| REDUXIN FORTE | 2 879 | 5.8% | 11.0% | 0.8 | 13 873 591 | 7.1% | 13.2% | 1.4 | -2.1% |
| SALVISAR | 11 510 | 14.5% | 1.7% | 0.2 | 6 210 171 | 13.4% | 1.7% | 0.2 | 0.1% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 36 668 | 3.5% | 14.1% | 0.1 | 84 968 932 | 3.2% | 10.6% | -0.1 | 2.8% |
| BRAINMAX | 8 534 | 2.0% | 100.0% | 0 | 30 008 435 | 3.6% | 100.0% | 0 | 2.0% |
| GOLDLINE PLUS | 56 909 | -3.8% | 45.9% | -0.9 | 188 693 462 | -2.8% | 37.6% | -0.8 | -2.0% |
| MIGRENIUM | 35 983 | 7.1% | 0.3% | 0 | 12 764 211 | 6.9% | 0.5% | 0 | 4.2% |
| MODELAX-N | 109 386 | -0.2% | 18.8% | -0.1 | 62 929 768 | 2.9% | 14.0% | 0.3 | 0.3% |
| REDUXIN CAPS | 40 074 | 0.3% | 32.3% | 0.7 | 219 573 916 | 1.5% | 43.8% | 1 | -2.0% |
| REDUXIN FORTE | 12 848 | -2.5% | 10.4% | -0.1 | 60 988 448 | -1.5% | 12.2% | -0.1 | -2.0% |
| SALVISAR | 42 810 | 13.5% | 1.4% | 0.2 | 23 255 651 | 14.8% | 1.4% | 0.2 | 1.1% |
ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе “MS of competitors” в блоке каждого бренда
ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the* last full month* and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection “MS of competitors” in sections for each brand
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "MODELAX-N SOL RECTAL USE 12.9 MG/ML+102.6 MG/ML+625 MG/ML 5 ML #20"
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "MODELAX-N SOL RECTAL USE 12.9 MG/ML+102.6 MG/ML+625 MG/ML 5 ML #20"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #90"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #10"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #30"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #60"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #90"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #20"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #20"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
[RUS] ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе “MS of competitors” в блоке каждого бренда
[ENG] ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the last full month and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection “MS of competitors” in sections for each brand
DATA SOURCES:
DSM: Sales
Palomars: TRPs